LivaNova PLC Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)0.91 Intrinsic Value $69.70median of 5 methods · middle span $54-$96based on filings through 30 Jun 2026 Market Price $74.70Price as of 1 Oct 2026 Near fair valueIntrinsic value is 7% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $4.1B Enterprise Value $3.9B Shares Outstanding 56.2M diluted Moat Rating Wide Next Earnings Date4 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary LivaNova PLC is executing strongly on its core Cardiopulmonary and Neuromodulation franchises while preparing to enter the high-growth, high-margin Obstructive Sleep Apnea (OSA) market. The company's Q1 2026 results demonstrated double-digit revenue growth and a return to GAAP profitability, prompting management to raise full-year 2026 guidance. With the FDA PMA approval of the aura6000 System backed by robust 12-month OSPREY clinical trial data, LivaNova is well-positioned to capture market share in sleep apnea, serving as a powerful long-term growth catalyst. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$75.00 Mean target$89.40 High · most bullish analyst$100.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $75.00 Slower-than-expected commercial uptake of the aura6000 system, combined with margin contraction in Neuromodulation due to competitive pressures and higher-than-expected cash outflows from the SNIA environmental liability, limits valuation expansion. Base CaseCentral scenario $89.40 Matches the consensus meanLivaNova achieves its raised FY 2026 constant-currency revenue growth guidance of 7.0% to 8.0% and adjusted diluted EPS of $4.20 to $4.30. Core businesses remain highly stable, and the company successfully prepares for the commercial rollout of its next-generation MRI-compatible OSA device in 2027. Bull CaseUpside scenario $100.00 Rapid market adoption of the aura6000 System for OSA following its H1 2027 launch, combined with sustained double-digit growth in the Cardiopulmonary segment driven by the Essenz Perfusion System, pushes revenue growth and operating margins well above consensus expectations. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |